Marat Fudim1, Christopher M O'Connor2, Hillary Mulder3, Adrian Coles3, Ankeet S Bhatt4, Andrew P Ambrosy5, William E Kraus6, Ileana L Piña7, David J Whellan8, Robert J Mentz5. 1. Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC. Electronic address: marat.fudim@dm.duke.edu. 2. Inova Heart and Vascular Institute, Fairfax, VA. 3. Duke Clinical Research Institute, Durham, NC. 4. Duke University Medical Center, Durham, NC. 5. Duke University Medical Center, Durham, NC; Duke Clinical Research Institute, Durham, NC. 6. Duke University Medical Center, Durham, NC; Duke Molecular Physiology Institute, Duke University School of Medicine, Duke, NC. 7. Albert Einstein, College of Medicine, New York, NY. 8. Thomas Jefferson University, Philadelphia, PA.
Abstract
BACKGROUND: The relationship between diuretic use or change in diuretic use and outcomes in chronic heart failure (HF) remains poorly defined. We evaluated the association between diuretic use and changes in health status, exercise capacity, and clinical events in a large randomized trial of subjects with HF. METHODS: HF-ACTION randomized 2,331 outpatients with HF and ejection fraction ≤35% toaerobic exercise training versus usual care. We grouped patients according to loop diuretic use from baseline through 6 months: continued use, never use, initiated, and discontinued. The association between diuretic use and changes in health status, exercise capacity, and clinical outcomes (all-cause mortality/hospitalization, cardiovascular mortality, and HF hospitalization) through 12 months was assessed using Cox proportional hazards models and generalized linear regression models, respectively. RESULTS:A total of 2,004 (86%) patients had complete data on diuretic use. There was no association between diuretic status and Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, or peak Vo2 in adjusted analyses (all P > .05). A dose increase was associated with decrease in 6-minute walk distance (-4.25 m, SE 1.12 m, P < .001) and change in Kansas City CardiomyopathyQuestionnaire overall score (-0.56 m, SE 0.24 m, P = .02). There were no between-group differences for all-cause death or hospitalization comparing continuous use versus never use (adjusted HR 0.91; 95% CI 0.72-1.15; P = .432). CONCLUSIONS: The initiation or discontinuation of diuretics over a 6-month time frame was not associated with a difference in mortality, hospitalizations, exercise, or health status outcomes, but a dose increase in HF patients was associated with worse exercise and health status outcomes.
RCT Entities:
BACKGROUND: The relationship between diuretic use or change in diuretic use and outcomes in chronic heart failure (HF) remains poorly defined. We evaluated the association between diuretic use and changes in health status, exercise capacity, and clinical events in a large randomized trial of subjects with HF. METHODS:HF-ACTION randomized 2,331 outpatients with HF and ejection fraction ≤35% to aerobic exercise training versus usual care. We grouped patients according to loop diuretic use from baseline through 6 months: continued use, never use, initiated, and discontinued. The association between diuretic use and changes in health status, exercise capacity, and clinical outcomes (all-cause mortality/hospitalization, cardiovascular mortality, and HF hospitalization) through 12 months was assessed using Cox proportional hazards models and generalized linear regression models, respectively. RESULTS: A total of 2,004 (86%) patients had complete data on diuretic use. There was no association between diuretic status and Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, or peak Vo2 in adjusted analyses (all P > .05). A dose increase was associated with decrease in 6-minute walk distance (-4.25 m, SE 1.12 m, P < .001) and change in Kansas City Cardiomyopathy Questionnaire overall score (-0.56 m, SE 0.24 m, P = .02). There were no between-group differences for all-cause death or hospitalization comparing continuous use versus never use (adjusted HR 0.91; 95% CI 0.72-1.15; P = .432). CONCLUSIONS: The initiation or discontinuation of diuretics over a 6-month time frame was not associated with a difference in mortality, hospitalizations, exercise, or health status outcomes, but a dose increase in HFpatients was associated with worse exercise and health status outcomes.
Authors: Peter K Bonfils; Morten Damgaard; Mustafa Taskiran; Jens Peter Goetze; Peter Norsk; Niels Gadsbøll Journal: Eur J Heart Fail Date: 2010-07-08 Impact factor: 15.534
Authors: Christopher M O'Connor; David J Whellan; Daniel Wojdyla; Eric Leifer; Robert M Clare; Stephen J Ellis; Lawrence J Fine; Jerome L Fleg; Faiez Zannad; Steven J Keteyian; Dalane W Kitzman; William E Kraus; David Rendall; Ileana L Piña; Lawton S Cooper; Mona Fiuzat; Kerry L Lee Journal: Circ Heart Fail Date: 2011-11-23 Impact factor: 8.790
Authors: David J Whellan; Christopher M O'Connor; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston-Miller; Jerome L Fleg; Kevin A Schulman; Ileana L Piña Journal: Am Heart J Date: 2007-02 Impact factor: 4.749
Authors: Petra Nijst; Frederik H Verbrugge; Philippe B Bertrand; Pieter Martens; Matthias Dupont; Olivier Drieskens; Joris Penders; W H Wilson Tang; Wilfried Mullens Journal: J Card Fail Date: 2016-08-22 Impact factor: 5.712
Authors: Christopher M O'Connor; David J Whellan; Kerry L Lee; Steven J Keteyian; Lawton S Cooper; Stephen J Ellis; Eric S Leifer; William E Kraus; Dalane W Kitzman; James A Blumenthal; David S Rendall; Nancy Houston Miller; Jerome L Fleg; Kevin A Schulman; Robert S McKelvie; Faiez Zannad; Ileana L Piña Journal: JAMA Date: 2009-04-08 Impact factor: 56.272
Authors: Michael Domanski; James Norman; Bertram Pitt; Mark Haigney; Stephen Hanlon; Eliot Peyster Journal: J Am Coll Cardiol Date: 2003-08-20 Impact factor: 24.094
Authors: F L Dini; S Ghio; C Klersy; A Rossi; A Simioniuc; L Scelsi; F T Genta; M Cicoira; L Tavazzi; P L Temporelli Journal: Int J Clin Pract Date: 2013-07 Impact factor: 2.503
Authors: Alice M Jackson; Pooja Dewan; Inder S Anand; Jan Bělohlávek; Olof Bengtsson; Rudolf A de Boer; Michael Böhm; David W Boulton; Vijay K Chopra; David L DeMets; Kieran F Docherty; Andrej Dukát; Peter J Greasley; Jonathan G Howlett; Silvio E Inzucchi; Tzvetana Katova; Lars Køber; Mikhail N Kosiborod; Anna Maria Langkilde; Daniel Lindholm; Charlotta E A Ljungman; Felipe A Martinez; Eileen O'Meara; Marc S Sabatine; Mikaela Sjöstrand; Scott D Solomon; Sergey Tereshchenko; Subodh Verma; Pardeep S Jhund; John J V McMurray Journal: Circulation Date: 2020-07-16 Impact factor: 29.690